Effect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes.

Exclusion Criteria

• •Inability to give informed consent.
• •Severe renal disease with eGFR \<25 ml/min/1.73m2.
• •Severe hepatic disease (plasma ALAT above 3 x upper limit of normal).
• •Active cancer diagnosis other than basal cell carcinoma.
• •Treatment with systemic steroids at time of randomization.
• •Bariatric surgery within 2 years or other gastrointestinal surgeries that induce chronic malabsorption.
• •Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake.
• •Chronic or acute pancreatitis.
• •Pregnancy or breastfeeding (see pregnancy below).
• •Poorly controlled medical condition, e.g. congestive heart failure (New York Heart Association III-IV or EF ≤ 40%), recent (within 3 months) stroke or acute myocardial infarction or any other condition that in the opinion of the investigator will put the trial participant at risk if participating in the trial.
• •Allergy to finerenone or any of the excipients contained in the drug.
• •Current systemic treatment with strong inhibitors of CYP3A4 (e.g. itraconazol, ketoconazole, ritonavir, cobicistat, clarithromycin) or strong inducers of CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital).
• •Current treatment with other MRAs (e.g. spironolactone, eplerenone etc.).
• •Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose- galactose malabsorption.
• •Addison's disease.
• •Contraindications to MRI.
• •Previous renal or heart transplantation.